Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04059484
Registration number
NCT04059484
Ethics application status
Date submitted
9/08/2019
Date registered
16/08/2019
Date last updated
24/04/2024
Titles & IDs
Public title
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
Query!
Scientific title
An Open Label Randomized Phase 2 Trial of Amcenestrant (SAR439859), Versus Endocrine Monotherapy as Per Physician's Choice in Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies
Query!
Secondary ID [1]
0
0
U1111-1217-2774
Query!
Secondary ID [2]
0
0
ACT16105
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
AMEERA-3
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer Metastatic
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Amcenestrant
Treatment: Drugs - Fulvestrant
Treatment: Drugs - Anastrozole
Treatment: Drugs - Letrozole
Treatment: Drugs - Exemestane
Treatment: Drugs - Tamoxifen
Experimental: Amcenestrant - Daily amcenestrant dose administered orally under fed or fast condition
Active Comparator: Fulvestrant/Aromatase inhibitors/Estrogen receptor modulator - Control treatment of the choice of the physician depending on each participant's medical condition and in accordance with the approved label may include 1 of the following treatments used as monotherapy.
Fulvestrant
Aromatase inhibitors (anastrozole, letrozole, exemestane)
Selective estrogen receptor modulator (Tamoxifen)
Treatment: Drugs: Amcenestrant
Pharmaceutical form: Capsule
Route of administration: Oral
Treatment: Drugs: Fulvestrant
Pharmaceutical form: Solution for injection
Route of administration: Intramuscular
Treatment: Drugs: Anastrozole
Pharmaceutical form:Tablets or capsules
Route of administration: Oral
Treatment: Drugs: Letrozole
Pharmaceutical form: Tablets or capsules
Route of administration: Oral
Treatment: Drugs: Exemestane
Pharmaceutical form: Tablets or capsules
Route of administration: Oral
Treatment: Drugs: Tamoxifen
Pharmaceutical form: Tablets or capsules
Route of administration: Oral
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS is defined as the time in months interval from the date of randomization to the date of first documented tumor progression as per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) assessed by independent central review (ICR) or death (due to any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [1]
0
0
From randomization to the date of first documented tumor progression or death due to any cause or data cut-off date whichever comes first (maximum duration: 116 weeks)
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as the time interval from the date of randomization to the date of documented death (due to any cause). In the absence of observation of death, survival time was censored to last date the participant is known to be alive or at the cut-off date, whichever comes first. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [1]
0
0
From randomization to the death due to any cause or data cut-off date whichever comes first (maximum duration: 116 weeks)
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Objective Response
Query!
Assessment method [2]
0
0
Objective response is defined as percentage of participants having a partial response (PR) or complete response (CR) according to the RECIST version 1.1 assessed by ICR. As per RECIST 1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Query!
Timepoint [2]
0
0
From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (maximum duration: 116 weeks)
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Disease Control
Query!
Assessment method [3]
0
0
Disease control is defined as percentage of participants having a confirmed CR, PR, or stable disease (SD) or Non-CR/Non-PD as BOR determined by ICR as per RECIST 1.1 from the date of randomization to the date of end of treatment. As per RECIST 1.1, CR: disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters. Non-CR/Non-PD: persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.
Query!
Timepoint [3]
0
0
From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (maximum duration: 116 weeks)
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Clinical Benefit
Query!
Assessment method [4]
0
0
Clinical Benefit is defined as percentage of participants having a confirmed CR, PR, SD, or Non-CR/Non-PD for at least 24 weeks determined by ICR as per RECIST 1.1 from the date of randomization to the date of end of treatment. As per RECIST 1.1, CR: disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters. Non-CR/Non-PD: persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.
Query!
Timepoint [4]
0
0
From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (maximum duration: 116 weeks)
Query!
Secondary outcome [5]
0
0
Duration of Response (DOR)
Query!
Assessment method [5]
0
0
DOR is defined as time (in months) from first documented evidence of CR or PR until progressive disease (PD) determined by ICR as per RECIST 1.1 or death from any cause, whichever occurs first. For participants with ongoing response at the time of the analysis, DOR was censored at the date of the last valid disease assessment not showing documented progression performed before the initiation of a new anticancer treatment (if any). As per RECIST 1.1, CR: disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.
Query!
Timepoint [5]
0
0
From the date of first response to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (maximum duration: 116 weeks)
Query!
Secondary outcome [6]
0
0
Progression Free Survival (PFS) According to Estrogen Receptor 1 Gene (ESR1) Mutation Status
Query!
Assessment method [6]
0
0
PFS defined as the time (in months) interval from the date of randomization to the date of first documented tumor progression as per RECIST 1.1 assessed by ICR or death (due to any cause), whichever comes first. Progression as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. The mutation status (wild type, mutant) of twelve specific mutations of the ESR1 gene was determined by multiplex droplet digital polymerase chain reaction (ddPCR), including their mutant frequency and concentration. Here, PFS is reported based on the ESR1 mutation status of participants: wild type and mutants. ESR1 was the gene encoding estrogen receptor alpha. ESR1 mutant type breast cancer was a disease where the ESR1 gene had a mutation (i.e., a type of error). ESR1 wild type breast cancer was a disease where the ESR1 gene was normal without a mutation. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [6]
0
0
From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (maximum duration: 116 weeks)
Query!
Secondary outcome [7]
0
0
Pharmacokinetics: Plasma Concentrations of Amcenestrant
Query!
Assessment method [7]
0
0
Amcenestrant plasma concentrations at specified time points are reported.
Query!
Timepoint [7]
0
0
Cycle 1 Day 1: 1.5 hours(h), 4h post-dose, Day 15: pre-dose, Cycle 2 Day 1: pre-dose, 1.5h, 4h, 8h post-dose, Cycle 3 Day 1: pre-dose, Cycle 4 Day 1: pre-dose, Cycle 6 Day 1: pre-dose
Query!
Secondary outcome [8]
0
0
Within-Participant Steady State Ctrough of Amcenestrant
Query!
Assessment method [8]
0
0
Within-participant Steady state Ctrough was defined as the median value of the Ctrough across study using plasma concentration of predose samples at Cycle 1 Day 15 and Day 1 of Cycle 2, 3, 4 and 6 for each individual participant. Average (mean) of all calculated Ctrough values for all participants across study (Cycle 1 Day 15 and Day 1 of Cycle 2, 3, 4 and 6 ) was derived and reported in this outcome measure.
Query!
Timepoint [8]
0
0
Predose on Cycle 1 Day 15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 4 Day 1; Cycle 6 Day 1
Query!
Secondary outcome [9]
0
0
Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30) Domain Scores
Query!
Assessment method [9]
0
0
EORTC-QLQ-C30: cancer-specific instrument with 30 questions for evaluation of new chemotherapy & assessment of participant reported outcome. These include 5 functional scales, 9 symptom scales, & Global Health Status/quality of life scale (GHS/QoL). All 14 items/domains were scored on scale of 1 (not at all) to 4 (very much) and GHS/QoL, scored on scale of 1 (very poor) to 7 (excellent). All scales are transformed from raw scores to linear scales ranging 0 to 100. Higher score for functional & GHS/QoL = higher level of functioning, & higher score for symptoms scales = higher symptom burden. Least Square (LS) mean and Standard Error (SE) are derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect. Average of LS mean change from baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 30]) was reported in this outcome measure.
Query!
Timepoint [9]
0
0
Baseline, overall treatment duration (Cycle 1 up to Cycle 30 [i.e.,116 weeks])
Query!
Secondary outcome [10]
0
0
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Visual Analog Scale (VAS) Score
Query!
Assessment method [10]
0
0
EQ-5D-5L is a standardized measure of health status, provides a simple, generic measure of health for clinical and economic appraisal, and consists of 2 sections: the EQ-5D-5L health state utility index (descriptive system) and the EQ-5D-5L VAS. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. LS mean and SE are derived from MMRM model with change from baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect. Average of LS mean change from Baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 30]) was reported in this outcome measure.
Query!
Timepoint [10]
0
0
Baseline, overall treatment duration (Cycle 1 up to Cycle 30 [i.e.,116 weeks])
Query!
Secondary outcome [11]
0
0
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Health Utility Index Value
Query!
Assessment method [11]
0
0
EQ-5D-5L: consists of 2 sections: EQ-5D-5L health state utility index (descriptive system) & VAS. The EQ-5D descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort & anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, & extreme problems. Response options are measured with 5-point Likert scale (for 5L version). The EQ-5D-5L responses are converted into single index utility score between 0 to 1, where higher score indicates better health state & lower score indicate worse health state. LS mean and SE are derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect. Average of LS mean change from baseline values overall treatment (i.e., each cycle [Cycle 1 up to Cycle 30]) was reported in this outcome measure.
Query!
Timepoint [11]
0
0
Baseline, overall treatment duration (Cycle 1 up to Cycle 30 [i.e.,116 weeks])
Query!
Secondary outcome [12]
0
0
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Breast Cancer Specific Module (EORTC-QLQ-BR23) Domain Scores
Query!
Assessment method [12]
0
0
QLQ-BR23: disease-specific Health-related QOL assesses impact of breast cancer & side effects of treatment. EORTC-QLQ-BR23 contains 23 items: multi-item scales & single-item measures. 4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) & 4 scales related to symptoms of disease or treatment (arm symptoms, breast symptoms, systemic therapy side effects, & upset by hair loss). All items scored 1 (not at all) to 4 (very much). Scores of all scales transformed from raw scores to linear scales ranging 0 to 100. Higher score for functional scales = better outcome; higher score for symptoms scales = higher symptom burden. LS mean and SE are derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect. Average of LS mean change from baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 30]) was reported.
Query!
Timepoint [12]
0
0
Baseline, overall treatment duration (Cycle 1 up to Cycle 30 [i.e.,116 weeks])
Query!
Eligibility
Key inclusion criteria
Inclusion criteria :
- 18 years or older.
- Histological or cytological diagnosis of adenocarcinoma of the breast.
- Locally advanced not amenable to radiation therapy or surgery in a curative intent,
and/or metastatic disease.
- Estrogen receptor(ER) positive status.
- Human epidermal growth factor receptor 2 negative status.
- Participants must have received no more than 1 prior chemotherapeutic or 1 targeted
therapy regimen for advanced/metastatic disease.
- In the main study, a prior treatment with a Cyclin-dependent kinase 4 and 6(CDK 4/6)
inhibitor is mandatory if this treatment is approved and can be reimbursed for this
participant. The percentage of participants without previous CDK 4/6 inhibitor will be
capped to 20%. In the Chinese extension cohort, previous treatment with a CDK 4/6
inhibitor will not be mandatory, and there will be no limitation to the number of
participants naïve to CDK4/6 inhibitor.
- Participants must present a secondary endocrine resistance to endocrine therapy
defined as: progression while on endocrine therapy after at least 6 months of
treatment for advanced breast cancer, or relapse while on adjuvant endocrine therapy
but after the first 2 years, or with a relapse within 12 months after completing
adjuvant endocrine therapy.
- Male or Female.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Eastern Cooperative Oncology Group performance status =>2.
- Medical history or ongoing gastrointestinal disorders potentially affecting the
absorption of amcenestrant. Participants unable to swallow normally and to take
capsules.
- Participant with any other cancer. Adequately treated basal cell or squamous cell skin
cancer or in situ cervical cancer or any other cancer from which the participant has
been disease free for greater than 3 years are allowed.
- Severe uncontrolled systemic disease at screening .
- Participants with known brain metastases that are untreated, symptomatic or require
therapy to control symptoms.
- Prior treatment with mammalian target of rapamycin inhibitors or any other selective
estrogen receptor degrader(SERD) compound, except fulvestrant if stopped for at least
3 months before randomization.
- Treatment with drugs that have the potential to inhibit Uridine'5
Diphospho-Glucuronosyl Transferase(UGT) less than 2 weeks before randomization.
- Treatment with strong Cytochrome P450 (CYP)3A inducers within 2 weeks before
randomization.
- Ongoing treatment with drugs that are sensitive substrate of organic anion
transporting polypeptide 1B1/B3(OATP1B1/B3) (asunaprevir, atorvastatin, bosentan,
danoprevir, fexofenadine, glyburide, nateglinide, pitavastatin, pravastatin,
replaglinide, rosuvastatin, and simvastatin acid).
- Treatment with anticancer agents (including investigational drugs) less than 3 weeks
before randomization.
- Inadequate hematological, coagulation, renal and liver functions.
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
22/10/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/09/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
367
Query!
Recruitment in Australia
Recruitment state(s)
QLD,WA
Query!
Recruitment hospital [1]
0
0
Investigational Site Number : 0360003 - South Brisbane
Query!
Recruitment hospital [2]
0
0
Investigational Site Number : 0360002 - Woolloongabba
Query!
Recruitment hospital [3]
0
0
Investigational Site Number : 0360001 - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Louisiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Hampshire
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Jersey
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Vermont
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Washington
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Wisconsin
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Buenos Aires
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Santa Fe
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
La Rioja
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Salta
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Charleroi
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Leuven
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Namur
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
Goiás
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
Rio Grande Do Sul
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
São Paulo
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Alberta
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Ontario
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Quebec
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Beijing
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Changchun
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Changsha
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Chengdu
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Chongqing
Query!
Country [32]
0
0
China
Query!
State/province [32]
0
0
Hangzhou
Query!
Country [33]
0
0
China
Query!
State/province [33]
0
0
Harbin
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Hefei
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Jinan
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Kunming
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Linyi
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Nanjing
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Tianjin
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Urumqi
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Wuhan
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Xuzhou
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Brno
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Novy Jicin
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Praha 4
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
ANGERS Cedex 02
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Creteil
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Marseille
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Paris
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Villejuif
Query!
Country [51]
0
0
Greece
Query!
State/province [51]
0
0
Heraklion
Query!
Country [52]
0
0
Greece
Query!
State/province [52]
0
0
Larisa
Query!
Country [53]
0
0
Greece
Query!
State/province [53]
0
0
Thessaloniki
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Jerusalem
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Petah-Tikva
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Tel Aviv
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Tel HaShomer
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Torino
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Milano
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Prato
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Aichi
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Chiba
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Gunma
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Kanagawa
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Osaka
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Saitama
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Tokyo
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Seoul-teukbyeolsi
Query!
Country [69]
0
0
Latvia
Query!
State/province [69]
0
0
Riga
Query!
Country [70]
0
0
Mexico
Query!
State/province [70]
0
0
Nuevo León
Query!
Country [71]
0
0
Mexico
Query!
State/province [71]
0
0
Mexico
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Veracruz
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Mazowieckie
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Wielkopolskie
Query!
Country [75]
0
0
Puerto Rico
Query!
State/province [75]
0
0
Ponce De Leon 735 Hato Rey
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Moscow
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Saint -Petersburg
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Barcelona [Barcelona]
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Catalunya [Cataluña]
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Málaga
Query!
Country [81]
0
0
Taiwan
Query!
State/province [81]
0
0
Taichung
Query!
Country [82]
0
0
Taiwan
Query!
State/province [82]
0
0
Tainan
Query!
Country [83]
0
0
Taiwan
Query!
State/province [83]
0
0
Taipei
Query!
Country [84]
0
0
Turkey
Query!
State/province [84]
0
0
Ankara
Query!
Country [85]
0
0
Turkey
Query!
State/province [85]
0
0
Edirne
Query!
Country [86]
0
0
Turkey
Query!
State/province [86]
0
0
Istanbul
Query!
Country [87]
0
0
Ukraine
Query!
State/province [87]
0
0
Kryvyi Rih
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Odesa
Query!
Country [89]
0
0
Ukraine
Query!
State/province [89]
0
0
Uzhgorod
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary Objective:
To determine whether amcenestrant per overall survival (os) improves progression free
survival (PFS) when compared with an endocrine monotherapy of the choice of the physician, in
participants with metastatic or locally advanced breast cancer
Secondary Objectives:
- To compare the overall survival in the 2 treatment arms
- To assess the objective response rate in the 2 treatment arms
- To evaluate the disease control rate in the 2 treatment arms
- To evaluate the clinical benefit rate in the 2 treatment arms
- To evaluate the duration of response in the 2 treatment arms
- To evaluate the PFS according to the estrogen receptor 1 gene (ESR1) mutation status in
the 2 treatment arms
- To evaluate the pharmacokinetics of amcenestrant as single agent
- To evaluate health-related quality of life in the 2 treatment arms
- To compare the overall safety profile in the 2 treatment arms
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04059484
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04059484
Download to PDF